Floatz logo

CDX 1140

Soft Tissue Sarcoma

University of Southern Californiamonoclonal_antibodyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

103 Active assets in the Soft Tissue Sarcoma cohort.

Asset / SponsorPhaseRating
Palbociclib
Brown University
Phase 2BB
Eloxatin
OHSU Knight Cancer Institute
Phase 2BB
FILGRASTIM
University of California, Irvine
Phase 3BB
Inno-206
GI Innovation, Inc.
Phase 3BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

CDX 1140 is also rated in:

primary peritoneal carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
endometrial serous adenocarcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
ovarian carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →